{"organizations": [], "uuid": "0381b553d4f5b50e7a803976d9869aa0fea60d50", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alnylam-retains-global-rights-to-l/brief-alnylam-retains-global-rights-to-lumasiran-investigational-rnai-therapeutic-for-treatment-of-primary-hyperoxaluria-type-1-idUSFWN1QU0PN", "country": "US", "domain_rank": 408, "title": "BRIEF-Alnylam Retains Global Rights To Lumasiran, Investigational RNAi Therapeutic For Treatment Of Primary Hyperoxaluria Type 1", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T13:08:00.000+02:00", "replies_count": 0, "uuid": "0381b553d4f5b50e7a803976d9869aa0fea60d50"}, "author": "", "url": "https://www.reuters.com/article/brief-alnylam-retains-global-rights-to-l/brief-alnylam-retains-global-rights-to-lumasiran-investigational-rnai-therapeutic-for-treatment-of-primary-hyperoxaluria-type-1-idUSFWN1QU0PN", "ord_in_thread": 0, "title": "BRIEF-Alnylam Retains Global Rights To Lumasiran, Investigational RNAi Therapeutic For Treatment Of Primary Hyperoxaluria Type 1", "locations": [], "entities": {"persons": [{"name": "investiga", "sentiment": "negative"}, {"name": "lumasiran", "sentiment": "none"}], "locations": [{"name": "lumasiran", "sentiment": "none"}], "organizations": [{"name": "alnylam pharmaceuticals inc", "sentiment": "none"}, {"name": "alnylam pharmaceuticals inc", "sentiment": "none"}, {"name": "treatment of primary hyperoxaluria type", "sentiment": "none"}, {"name": "alnylam", "sentiment": "none"}, {"name": "sanofi", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 12, 2018 / 11:10 AM / in 8 minutes BRIEF-Alnylam Retains Global Rights To Lumasiran, Investigational RNAi Therapeutic For Treatment Of Primary Hyperoxaluria Type 1 Reuters Staff 1 Min Read March 12 (Reuters) - Alnylam Pharmaceuticals Inc: * ALNYLAM RETAINS GLOBAL RIGHTS TO LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) * ALNYLAM PHARMACEUTICALS INC - ‍COMPANY PLANS TO ACCELERATE DEVELOPMENT WITH PHASE 3 START IN LATE 2018​ * ALNYLAM PHARMACEUTICALS INC - ‍LUMASIRAN GRANTED BREAKTHROUGH THERAPY DESIGNATION BY UNITED STATES FOOD AND DRUG ADMINISTRATION​ * ALNYLAM PHARMACEUTICALS INC - ‍SANOFI GENZYME HAS DECLINED ITS OPT-IN FOR DEVELOPMENT AND COMMERCIALIZATION OF LUMASIRAN​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-12T13:08:00.000+02:00", "crawled": "2018-03-12T13:21:30.001+02:00", "highlightTitle": ""}